A team of researchers organized by Kip Guy (University of Kentucky College of Pharmacy dean), including those at UK, St. Jude Children’s Research Hospital in Tennessee, Eisai in both the United States and Japan, Medicines for Malaria Venture (MMV) in Switzerland and QIMR in Australia, discovered a new, fast-acting anti-malarial compound that has shown promise in fighting malaria. The compound, SJ733, is one of the first in a new class of anti-malarial compounds to reach clinical trials, which are now in Phase II.
Produced by Research Communications at the University of Kentucky.
